Core B Medicinal Chemistry

核心 B 药物化学

基本信息

批准号：
10613886
负责人：
Joel Stephen Freundlich
金额：
$ 43.54万
依托单位：
HACKENSACK UNIVERSITY MEDICAL CENTER
依托单位国家：
美国
项目类别：
财政年份：
2019
资助国家：
美国
起止时间：
2019-05-01 至 2024-04-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10613886
关键词：
Acceleration Address Amino Acids Anabolism Anti-Bacterial Agents Antibiotics Bacterial Infections Biogenesis Biological Biological Assay Biology Cell Wall Chemicals Chemistry Clinical Collaborations Competence Complement Complex Data Development Doctor of Philosophy Drug Kinetics Evaluation Evolution Faculty Foundations Gene Cluster Generations Grant Growth Human Resources Individual Industrialization Industry Infection Lead Learning Mind Mining Mission Multi-Drug Resistance Mycobacterium abscessus Narrative Medicine Nature Oxazolidinones Peptide Synthesis Pharmaceutical Chemistry Pharmacologic Substance Phloroglucinol Postdoctoral Fellow Preparation Probability Process Publications Research Resources Respiration Rifamycins Scientist Series Source Structure-Activity Relationship Subgroup Techniques Therapeutic Time Toxic effect Translating Translations Validation Vision Work cell envelope chemical resource cheminformatics cost cost efficient design drug discovery experience follow-up global health inhibitor innovation insight lead optimization member novel novel lead compound preclinical development prevent programs scale up screening skills small molecule structural biology

项目摘要

Abstract The Medicinal Chemistry (MedChem) Core has been formed to address the urgent need for novel antibacterial agents. The MedChem Core will work seamlessly with the Project Teams and other Cores to drive the time- and cost-efficient discovery and development of novel lead compounds to target high-threat bacterial infections. Critical to its mission are its competencies in industrial and academic medicinal chemistry, cheminformatics, and structural biology, which are complemented by decades of experiences with the fundamental biology of the relevant bacterial agents. The MedChem Core will aid in the confirmation of hits discovered through computation or experimental screens, evolve these to early and then optimized leads following a defined workflow with quantitative metrics for molecules at each stage in the process. The MedChem Core will collaborate on projects focused on the discovery and development of A) phloroglucinol and myxopyronin antibacterials, B) rifamycin and oxazolidinone agents against Mycobacterium abscessus, C) antituberculars targeting cell wall biosynthesis or respiration, D) antibiotics suggested by mining of biosynthetic gene clusters, and E) bacterial cell envelope biogenesis inhibitors to prevent Gram-negative multi-drug resistant infections.

抽象的药物化学 (MedChem) 核心的成立是为了解决新型药物的迫切需求抗菌剂。 MedChem 核心将与项目团队和其他核心无缝合作，以推动以时间和成本效益的方式发现和开发针对高威胁细菌的新型先导化合物感染。其使命的关键在于其在工业和学术药物化学方面的能力，化学信息学和结构生物学，并辅以数十年的经验相关细菌制剂的基础生物学。 MedChem 核心将有助于确认命中通过计算或实验筛选发现，将其发展为早期和优化的线索遵循定义的工作流程，并在过程的每个阶段对分子进行定量指标。这 MedChem Core 将合作开展专注于发现和开发 A) 间苯三酚的项目和粘吡罗宁抗菌剂，B) 利福霉素和恶唑烷酮药物对抗脓肿分枝杆菌，C) 针对细胞壁生物合成或呼吸作用的抗结核药物，D) 通过生物合成挖掘得出的抗生素基因簇，和E）细菌细胞包膜生物发生抑制剂，以防止革兰氏阴性多药耐药感染。